Suzhou Ribo Life Science Co., Ltd. Class H (6938) Receives a Buy from CICCTip Ranks·Sep 3 at 04:05 AM06938+2.80%
From Biotech Breakthroughs to Consumer Shifts: Resurgence Signals in HK StocksGlobal Report·Sep 1 at 11:33 AM02632-0.07%06938+2.80%
Earnings Divergence: H&H Group Profits Surge While Aviation and Pharma Lag in Mid-2026Global Report·Sep 1 at 09:17 AM026050.00%02357+2.76%
Weekly Recap | RIBOLIFE-B +0.65%, first-half swing to profitWeekly Review·Aug 29 at 04:52 AM06938+2.80%
Suzhou Ribo Life Science swings to FY26 H1 profit of RMB 23.45 million; revenue rises to RMB 419.74 millionPUBT·Aug 27 at 11:14 AM06938+2.80%MDGL-0.28%
Suzhou Ribo Life Science board meets to review interim results, consider dividendPUBT·Aug 17 at 08:45 AM06938+2.80%
The Limits of Capital Aggregation: Structural Discounts in the Uncategorized Tail of Hong Kong StocksGlobal Report·Aug 13 at 09:44 AM01978-1.78%06938+2.80%
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH ExpansionSimplywall·Aug 9 at 11:38 AMMDGL-0.28%06938+2.80%
Suzhou Ribo wins EMA approval for Phase 2b vortosiran trial in stroke prevention for atrial fibrillationPUBT·Jul 28 at 11:58 AM06938+2.80%
Ribo reports vortosiran Phase IIa trial results for coronary artery diseaseWorldPharmaceuticals·Jul 23 at 11:38 AM06938+2.80%
10:11 ETRibo revela datos positivos del ensayo de fase 2a de vortosiranprnewswire·Jul 22 at 02:13 PM06938+2.80%
Suzhou Ribo Reports First Global Proof-of-Concept for siRNA FXI Therapy in CADTip Ranks·Jul 22 at 08:40 AM06938+2.80%
Suzhou Ribo files HKEX next-day return disclosing share repurchase at HKD 48.5 avg pricePUBT·Jul 14 at 10:53 AM06938+2.80%
